Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Named patient program of KIMOZO® (temozolomide) in European Countries

Next Previous
Trial Profile

Named patient program of KIMOZO® (temozolomide) in European Countries

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Cancer; Glioblastoma; Glioma; Neuroblastoma
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 25 Apr 2023 New trial record
  • 18 Apr 2023 According to a ORPHELIA Pharma media release, the company has signed an exclusive agreement to manage the supply and distribution of Ped-TMZ (temozolomide 40 mg/ml, oral suspension) with Tanner Pharma Group to meet the special demands which may come from physicians for this unapproved pediatric form of temozolomide. Under the terms of the agreement, Tanner Pharma will provide access to KIMOZO via a named patient program in European countries.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top